Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

September 15, 2022

Study Completion Date

September 15, 2022

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Apatinib mesylate tablet

The dose of apatinib mesylate tablets is 250mg, oral, qd, continuous administration, 4 weeks (28 days) as an observation cycle.

DRUG

PD-1

The dose of PD - 1 is 200 mg/ time, intravenous injection, q2w, 4 weeks (28 days) for an observation period.

Trial Locations (5)

Unknown

Guilin Medical University, Guilin

Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin

People's Hospital of Laibin, Laibin

People's Hospital of Lingshan, Linshan

Wuzhou Red Cross Hospital, Wuzhou

All Listed Sponsors
collaborator

Wuzhou Red Cross Hospital

OTHER

collaborator

Guangxi Naxishan Hospital

OTHER

collaborator

Laibin People's Hospital

OTHER

collaborator

People's Hospital of Lingshan

UNKNOWN

lead

Wei Jiang

OTHER

NCT04350190 - Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter